Huangpu makes breakthroughs in anti-cancer drug development

The biopharmaceutical base of Akeso in China-Singapore Guangzhou Knowledge City.

Cadonilimab (PD-1/CTLA-4), the first dual immune checkpoint inhibitor to treat cancer in the world that was developed by Huangpu-based biopharmaceutical company Akeso, was put on the market on July 9.

Akeso focuses on the development and commercialization of innovative therapeutic antibodies for oncology and immunology.

Cadonilimab (PD-1/CTLA-4) received marketing approval from the National Medical Products Administration of China on June 29 for the treatment of recurrent or metastatic cervical cancer (R/M CC) patients who progressed on or after platinum-based chemotherapy.

According to clinical research data, the median overall survival of Cadonilimab (PD-1/CTLA-4) in R/M CC patients is 17.51 months, eight to 13 months longer than other approved therapies.

The success of Cadonilimab (PD-1/CTLA-4) not only shows that China's innovative biotech companies are starting to reap the fruits of years of R&D investments, but also demonstrates that Chinese biotech companies like Akeso are catching up with global pharmaceutical companies quickly in innovative drug development.

Share - WeChat